Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 132 participants.

Also called NCT02490904

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 132 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02490904
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT02490904. Randomized; quadruple masking; primary purpose treatment. Start 2016-10-19 (actual); primary completion 2021-11-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)
Acronym
EPURE
Condition
End-stage Renal Disease
Intervention (Drug)
Eplerenone
Intervention (Drug)
Placebo
Lead sponsor
Central Hospital, Nancy, France (class: other)

Record details

Record id
cardio:ct-nct02490904
Content hash
8a202ba8f2dae8eb03c977a9c14318bc6d4dd2ab609d5ec2faa2b9ae9cc1b57b